Gemlapodect
Modify Date: 2024-04-06 14:42:26
Gemlapodect structure
|
Common Name | Gemlapodect | ||
|---|---|---|---|---|
| CAS Number | 1380329-87-2 | Molecular Weight | 431.45 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H21N7O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of GemlapodectGemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia[1]. |
| Name | Gemlapodect |
|---|
| Description | Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia[1]. |
|---|---|
| Related Catalog | |
| Target |
PDE10A |
| In Vivo | Gemlapodect (5-15 mg；口服；一天一次持续 6 周) 显著改善儿童期发作性流利性障碍 (COFD) 患者的工作和生活社会功能，显示出生物安全性[2]。 Gemlapodect (10 mg/kg；口服；单剂量) 在 9 周龄的 SD 大鼠中不改变葡萄糖耐受性。[2]。 Gemlapodect (0.3 mg/kg；口服；一天一次持续 8 天) 在 10 周龄的 SD 大鼠中诱导葡萄糖耐受性轻微改善，空腹血糖无变化，空腹胰岛素降低[2]。 Animal Model: Adult male patients with COFD (18-50 years old)[2]. Dosage: 5-15 mg. Administration: Oral gavage; once daily for 6 weeks. Result: Improved the Stuttering, work, social life, family life and home responsibilities of COFD patients and showed biosafety. Animal Model: 9 weeks or 10 weeks male SD rats[2]. Dosage: 0.3 mg/kg or 10 mg/kg. Administration: Oral gavage; once daily for 1 or 8 days. Result: Showed insignificantly change of glucose tolerance in healthy rats. |
| References |
| Molecular Formula | C22H21N7O3 |
|---|---|
| Molecular Weight | 431.45 |